<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247142</url>
  </required_header>
  <id_info>
    <org_study_id>S52756</org_study_id>
    <nct_id>NCT01247142</nct_id>
  </id_info>
  <brief_title>Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive
      pulmonary aspergillosis in exhaled breath condensate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised
      patients. The poor prognosis of the disease is partly attributed to difficulties encountered
      with the diagnosis of this infection. Invasive sampling procedures are often precluded in
      these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently
      there has been increasing interest in the investigation of the lungs by noninvasive means
      including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled
      and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the
      EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of
      biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC)</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Invasive pulmonary aspergillosis (IPA)</arm_group_label>
    <description>Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients without signs of infection.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      exhaled breath condensate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized adult patients of the department of Hematology or Intensive Care Unit,
        University Hospital, Leuven, Belgium
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalisation in the hematology or intensive care department

          -  age &gt; 16 years

          -  informed consent

          -  proven or probable IPA (EORTC/ MSG criteria)

          -  galactomannan positivity in BAL or serum

        Exclusion Criteria:

          -  age &lt; 16 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Edith Vermeulen</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <keyword>invasive pulmonary aspergillosis</keyword>
  <keyword>exhaled breath condensate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

